New York City-based Mount Sinai Health System and RenalytixAI, a subsidiary of EKF Diagnostics, entered into a multiyear license and collaboration agreement to commercialize a set of artificial intelligence tools focused on kidney care.
The partnership's first product will leverage data from more than 3 million patient health records held in Mount Sinai Health System's BioMe BioBank repository to create an AI system that monitors and flags patients at risk for developing kidney disease.
Mount Sinai and RenalytixAI officials expect the product to launch in the second quarter of 2019. Prior to the launch, RenalytixAI plans to pursue clinical utility trials with academic medical centers and pharmaceutical companies in the U.S. and Europe.
"Our ability to apply the power of artificial intelligence against such a deep repository of clinical data in combination with prognostic biomarkers has the potential to change the game for all of our patients with diabetes and other populations at risk for kidney disease," Barbara Murphy, MD, dean for clinical integration and population health management at the Icahn School of Medicine at Mount Sinai, said in a June 1 statement.
Dr. Murphy is also chair for the department of internal medicine at the Icahn School of Medicine and chair of RenalytixAI's scientific advisory board.